MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Bio-IT World
January 21, 2005
Best Practices 2005: Strut Your Stuff Organizations are invited to strut their stuff for Bio*IT World's annual awards program. mark for My Articles similar articles
Bio-IT World
August 2005
Kevin Davies
Special Report: Bio-IT World Best Practices 2005 Each year, the Best Practices awards program spotlights examples of the most outstanding innovations, technologies, and practices in the drug discovery pipeline. mark for My Articles similar articles
Bio-IT World
August 18, 2004
John Russell
A Dozen Sparkling Gems A snapshot of deserving Best Practices Awards entries: Locus Pharmaceuticals... Children's Memorial Hospital, Chicago... XOMA... University of Texas Health Science Center... etc. mark for My Articles similar articles
Bio-IT World
August 18, 2004
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. mark for My Articles similar articles
Bio-IT World
April 16, 2004
Best of the Best, Sir The FDA wants to change its ways and share its accumulated wisdom as part of a focused attack on costly, unpredictable product development. mark for My Articles similar articles
Bio-IT World
February 2007
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. mark for My Articles similar articles
Bio-IT World
August 2005
Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects. mark for My Articles similar articles
Bio-IT World
August 18, 2004
John Russell
Curbing a Killer Iconix Pharmaceuticals is working on building biomarkers that can predict toxicity and efficacy. mark for My Articles similar articles
Bio-IT World
August 18, 2004
Anthony Strattner
Opportunity to Gain or Lose A keynote speaker at Best Practices ceremony asserts that drug-development science -- those activities that go beyond translational science and into product testing and commercialization -- has stagnated, causing a pipeline problem. mark for My Articles similar articles
Bio-IT World
August 2005
Best Practices 2005 Winners Winners of the Best Practices awards include an innovative drug safety monitoring system, an integrated genomics gateway, and a genotyping pipeline. mark for My Articles similar articles
Bio-IT World
November 2005
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. mark for My Articles similar articles
Bio-IT World
July 15, 2003
The BRAIN Behind BCM's Clinical Trials What ultimately came to be called the Biomedical Research and Information Network, or BRAIN, took two years to build and cost Baylor College of Medicine $1.5 million. Yet no one doubts the value of the investment. mark for My Articles similar articles
The Motley Fool
June 21, 2010
Erin Kutz
Curis Misses Mark in Drug Trial; Genzyme Elects Board; GTC Cuts Jobs; and More Boston-Area Life Sciences News These drug and biomedical companies made news last week. mark for My Articles similar articles
Bio-IT World
March 8, 2005
Coming Attractions Ten reasons why you can't miss the Bio*IT World Conference + Expo in May. Headlines and Legends... Advances in Genomic Medicine... IT Solutions for Drug Discovery... etc. mark for My Articles similar articles
Bio-IT World
April 2006
Kevin Davies
Bio*IT World's New Beginning Cambridge Healthtech Institute, along with its new acquisition of Bio*IT World, under the new name of Cambridge Bio Collaborative will become the key information and conference resource for the industry. mark for My Articles similar articles
The Motley Fool
October 27, 2010
Ralph Casale
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. mark for My Articles similar articles
Bio-IT World
December 15, 2003
Mark D. Uehling
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. mark for My Articles similar articles
Bio-IT World
February 2006
Kevin Davies
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. mark for My Articles similar articles
Bio-IT World
April 2006
Phillips Kuhl
A Healthy Combination Bio*IT World has become a part of Cambridge Healthtech Institute (CHI). mark for My Articles similar articles
Bio-IT World
February 18, 2004
It's Showtime! The 2004 Bio*IT World Conference + Expo promises to be our most exceptional event yet. mark for My Articles similar articles
Bio-IT World
Dec 2006/Jan 2007
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. mark for My Articles similar articles
Bio-IT World
March 2006
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. mark for My Articles similar articles
Chemistry World
November 2009
Bibiana Campos-Seijo
Editorial: Ringing in the Nobels This year the chemistry prize seems to have once again caused a bit of a commotion. The criticism? Well, some in the scientific community have suggested that the research had too strong a biological focus. mark for My Articles similar articles
Bio-IT World
February 2006
News Blast Franklin Award... Improved Sensitivity... Discovery Tag Team... NIH Screening Begins... mark for My Articles similar articles
Bio-IT World
November 12, 2002
Michael Goldman
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? mark for My Articles similar articles
Bio-IT World
March 8, 2005
Patricia Reilly
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending. mark for My Articles similar articles
Bio-IT World
November 2006
Kevin Davies
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. mark for My Articles similar articles
Bio-IT World
August 13, 2002
Russell & Dodge
Necessary Liaisons: Making Standards Work Caroline Kovac, IBM Corp.'s general manager for life sciences, talks about the need for standards and her take on the troubled informatics world. mark for My Articles similar articles
Bio-IT World
September 2005
Kevin Davies
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. mark for My Articles similar articles
CIO
October 15, 2001
Stephanie Overby
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... mark for My Articles similar articles
Bio-IT World
April 15, 2003
Mark D. Uehling
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. mark for My Articles similar articles